Trinity Biotech projects it reached Adjusted EBITDA1 -positive operations during Q2 2025 and expects to be Adjusted EBITDA1 positive going forward, reflecting continued strong execution on its ...

Trinity Biotech’s patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029DUBLIN, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc ...

Review Trinity Biotech PLC ADR (TRIB:XNAS) stock and the current sustainability and ESG risk rating to help with your investing decisions.

DUBLIN, July 01, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including ...

Trinity Biotech plc (TRIB) - 20-F - Annual and Transition Report (foreign private issuer) SEC FilingsThu, May 15 ...

As you wade through biotech penny stocks, you are sure to find rampant speculation over COVID-19 treatments. Companies know they can quickly boost stock prices with little more than a press release.

1 day ago Ireland’s housing crisis, part 2: A ten-point plan for the next six months 1 day ago TikTok cuts ‘handful’ of Irish roles 1 day ago Irish Ferries in hot water after snubbing Welsh inquiry ...

J&J's announcement came just hours after GSK confirmed it had agreed a $1 billion deal to buy cancer biotech IDRx and its KIT inhibitor for gastrointestinal stromal tumours (GIST).